{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:01:43Z","timestamp":1788566503083,"version":"build-2803163510"},"reference-count":22,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"publisher","award":["REC65-399-38-2"],"award-info":[{"award-number":["REC65-399-38-2"]}],"id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"publisher","award":["MR-PSU: 66-38-23-115"],"award-info":[{"award-number":["MR-PSU: 66-38-23-115"]}],"id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"publisher","award":["PRP6605030330"],"award-info":[{"award-number":["PRP6605030330"]}],"id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"publisher","award":["8\/2023"],"award-info":[{"award-number":["8\/2023"]}],"id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Prince of Songkla University","award":["REC65-399-38-2"],"award-info":[{"award-number":["REC65-399-38-2"]}]},{"name":"Prince of Songkla University","award":["MR-PSU: 66-38-23-115"],"award-info":[{"award-number":["MR-PSU: 66-38-23-115"]}]},{"name":"Prince of Songkla University","award":["PRP6605030330"],"award-info":[{"award-number":["PRP6605030330"]}]},{"name":"Prince of Songkla University","award":["8\/2023"],"award-info":[{"award-number":["8\/2023"]}]},{"name":"RSU Research Institute of Rangsit University","award":["REC65-399-38-2"],"award-info":[{"award-number":["REC65-399-38-2"]}]},{"name":"RSU Research Institute of Rangsit University","award":["MR-PSU: 66-38-23-115"],"award-info":[{"award-number":["MR-PSU: 66-38-23-115"]}]},{"name":"RSU Research Institute of Rangsit University","award":["PRP6605030330"],"award-info":[{"award-number":["PRP6605030330"]}]},{"name":"RSU Research Institute of Rangsit University","award":["8\/2023"],"award-info":[{"award-number":["8\/2023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>This research aimed to determine the target protein and molecular mechanism of trans-(\u00b1)-kusunokinin (KU) derivatives ((\u00b1)-arctigenin (ARC) and trans-(\u00b1)-TTPG-B). Molecular docking was used to predict potential synthesized (\u00b1)-KU targets among 22 proteins. The (+)-TTPG-B bound HSP90\u03b1 better than EC44, native (\u00b1)-KU and trans-(\u00b1)-ARC. In contrast, (\u2212)-ARC bound PI3K more strongly than any other test compound. CSF1R and AKR1B1 were not supposed to be the target of (\u00b1)-TTPG-B and (\u00b1)-ARC, unlike native (\u00b1)-KU. The (+)-TTPG-B bound Tyr139 and Trp162 of HSP90\u03b1. Moreover, (\u2212)-ARC bound PI3K via hydrogen bonds and \u03c0-\u03c0 stacking at distinct amino acids, which was different from the other tested compounds. Using half of the IC50 concentration, (\u00b1)-TTPG-B, (\u00b1)-KU and (\u00b1)-ARC enhanced cell cycle arrest at the G0\/G1 phase after 12 h and 24 h on KKU-M213 (CCA) cells. The (\u00b1)-TTPG-B showed a stronger inhibitory effect than (\u00b1)-ARC and (\u00b1)-KU on HSP90\u03b1, PI3K, HSP90\u03b2, c-Myc, AKT, MEK1, CyclinB1, CyclinD1, and CDK1 for 24 and 48 h after treatment with the same concentration (0.015 \u00b5M). Thus, trans-(\u00b1)-TTPG-B, a newly synthesized compound, has pharmacological potential for development as a target therapy for CCA treatment.<\/jats:p>","DOI":"10.3390\/molecules28217342","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T13:26:55Z","timestamp":1698672415000},"page":"7342","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Trans-(\u00b1)-TTPG-B Attenuates Cell Cycle Progression and Inhibits Cell Proliferation on Cholangiocarcinoma Cells"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-4392","authenticated-orcid":false,"given":"Thidarath","family":"Rattanaburee","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"},{"name":"Biochemistry Unit, Department of Medical Sciences, Faculty of Science, Rangsit University, Pathum Thani 12000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chompunud","family":"Chompunud Na Ayudhya","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienthong","family":"Thongpanchang","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-7519","authenticated-orcid":false,"given":"Varomyalin","family":"Tipmanee","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9223-5282","authenticated-orcid":false,"given":"Potchanapond","family":"Graidist","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Simile, M.M., Bagella, P., Vidili, G., Spanu, A., Manetti, R., Seddaiu, M.A., Babudieri, S., Madeddu, G., Serra, P.A., and Altana, M. (2019). Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina, 55.","DOI":"10.3390\/medicina55020042"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cho, S.M., Esmail, A., Raza, A., Dacha, S., and Abdelrahim, M. (2022). Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma. Cancers, 14.","DOI":"10.3390\/cancers14112641"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_5","first-page":"43","article-title":"Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance","volume":"39","author":"Fouassier","year":"2019","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, L., Zhao, X., Fu, J., Xu, W., and Yuan, J. (2021). The Role of Tumour Metabolism in Cisplatin Resistance. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.691795"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41416-019-0523-5","article-title":"Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS\/RAF\/MEK\/ERK pathway: Phase Ib study","volume":"121","author":"Kim","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rattanaburee, T., Thongpanchang, T., Wongma, K., Tedasen, A., Sukpondma, Y., and Graidist, P. (2019). Anticancer activity of synthetic (\u00b1)-kusunokinin and its derivative (\u00b1)-bursehernin on human cancer cell lines. Biomed. Pharmacother. Biomed. Pharmacother., 117.","DOI":"10.1016\/j.biopha.2019.109115"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"173311","DOI":"10.1016\/j.ejphar.2020.173311","article-title":"(-)-Kusunokinin inhibits breast cancer in N-nitrosomethylurea-induced mammary tumor rats","volume":"882","author":"Tedasen","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rattanaburee, T., Tipmanee, V., Tedasen, A., Thongpanchang, T., and Graidist, P. (2020). Inhibition of CSF1R and AKT by (\u00b1)-kusunokinin hinders breast cancer cell proliferation. Biomed. Pharmacother. Biomed. Pharmacother., 129.","DOI":"10.1016\/j.biopha.2020.110361"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/acsomega.0c05102","article-title":"(-)-Kusunokinin as a Potential Aldose Reductase Inhibitor: Equivalency Observed via AKR1B1 Dynamics Simulation","volume":"6","author":"Tanawattanasuntorn","year":"2021","journal-title":"ACS Omega"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tanawattanasuntorn, T., Rattanaburee, T., Thongpanchang, T., and Graidist, P. (2022). Trans-(\u00b1)-Kusunokinin Binding to AKR1B1 Inhibits Oxidative Stress and Proteins Involved in Migration in Aggressive Breast Cancer. Antioxid., 11.","DOI":"10.3390\/antiox11122347"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rattanaburee, T., Sermmai, P., Tangthana-Umrung, K., Thongpanchang, T., and Graidist, P. (2022). Anticancer Activity of (\u00b1)-Kusunokinin Derivatives towards Cholangiocarcinoma Cells. Molecules, 27.","DOI":"10.3390\/molecules27238291"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10735-023-10119-8","article-title":"The chaperone system in cancer therapies: Hsp90","volume":"54","author":"Basset","year":"2023","journal-title":"J. Mol. Histol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhao, Q., Zhu, H.P., Xie, X., Mao, Q., Liu, Y.Q., He, X.H., Peng, C., Jiang, Q.L., and Huang, W. (2020). Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051845"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"El-Shafey, H.W., Gomaa, R.M., El-Messery, S.M., and Goda, F.E. (2020). Synthetic approaches, anticancer potential, HSP90 inhibition, multitarget evaluation, molecular modeling and apoptosis mechanistic study of thioquinazolinone skeleton: Promising antibreast cancer agent. Bioorganic Chem., 101.","DOI":"10.1016\/j.bioorg.2020.103987"},{"key":"ref_17","first-page":"2590","article-title":"A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K\/AKT\/mTOR\/MEK in multiple cancers","volume":"11","author":"Lawal","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jksus.2019.01.011","article-title":"Molecular docking studies on the interaction of NCI anticancer analogues with human Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit","volume":"31","author":"Arthur","year":"2019","journal-title":"J. King Saud. Univ. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"174215","DOI":"10.1016\/j.ejphar.2021.174215","article-title":"A novel evodiamine amino derivative as a PI3K\/AKT signaling pathway modulator that induces apoptosis in small cell lung cancer cells","volume":"906","author":"Wang","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_20","first-page":"e26233","article-title":"Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review","volume":"14","author":"Proskuriakova","year":"2022","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","first-page":"17","article-title":"New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential","volume":"12","author":"Li","year":"2009","journal-title":"Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer. Chemother."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/21\/7342\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:14:12Z","timestamp":1760130852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/21\/7342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":22,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["molecules28217342"],"URL":"https:\/\/doi.org\/10.3390\/molecules28217342","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}